H.C. Wainwright analyst Andres Maldonado raised the firm’s price target on CG Oncology (CGON) to $100 from $80 and keeps a Buy rating on the shares as part of a PIVOT-006 study preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology price target raised to $90 from $60 at UBS
- Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
- CG Oncology price target raised to $72 from $65 at BofA
- Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward
- CG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential